New CenterWatch Report Finds US Investigative Site Market Ripe for Consolidation Driven by European SMOs
CenterWatch reports that the fragmented US investigative site market is poised for acquisitions that may be driven by the most unlikely of sources: large European site management organizations (SMOs). The report, released in the January issue of The CenterWatch Monthly, provides an in-depth look at the infrastructure and strategies of the European companies likely to drive this wave of consolidation. The report signals opportunity and change for clinical research professionals in the US.
US investigative sites experienced an intense period of consolidation in the mid-to-late 1990s. At that time, venture-backed companies were on a buying spree to build large networks of physician investigators and standardize the management and conduct of industry-funded clinical trials. Since 2004, however, nearly all SMOs in the US. have either exited the clinical research market or diversified into other business areas. The investigative site landscape in the US. has become more fragmented, comprised of several thousand small research centers and two dozen medium-sized regional networks of practicing physicians participating in clinical trials.
CenterWatch now reports that a new type of SMO has been quietly growing in Europe, expanding into emerging regions including Latin America, India, and China during the late 2000s with ambitious plans to enter the US market in 2011. The complete report can be found in The CenterWatch Monthly, released today. Coverage includes detailed profiles of and interviews with the European SMOs driving this consolidation, and reaction from US clinical research professionals.
The CenterWatch Monthly is an in-depth newsletter covering the clinical trials industry, offering professionals at investigative sites, CROs and drug sponsors the latest news, trends, and grant opportunities. For subscription information visit the store at www.centerwatch.com.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
